DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Tocqueville Asset Management L.P.

Tocqueville Asset Management L.P. increased its position in DexCom, Inc. (NASDAQ:DXCM) by 8.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,735 shares of the medical device company’s stock after buying an additional 2,515 shares during the period. Tocqueville Asset Management L.P.’s holdings in DexCom were worth $4,755,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Blair William & Co. IL increased its position in DexCom by 4.6% during the first quarter. Blair William & Co. IL now owns 1,010,355 shares of the medical device company’s stock worth $120,333,000 after purchasing an additional 44,803 shares during the last quarter. OLD National Bancorp IN increased its position in DexCom by 1.1% during the second quarter. OLD National Bancorp IN now owns 9,838 shares of the medical device company’s stock worth $1,474,000 after purchasing an additional 108 shares during the last quarter. Virginia Retirement Systems ET AL increased its position in DexCom by 230.6% during the first quarter. Virginia Retirement Systems ET AL now owns 16,200 shares of the medical device company’s stock worth $1,929,000 after purchasing an additional 11,300 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its position in DexCom by 32.0% during the first quarter. Robeco Institutional Asset Management B.V. now owns 162,127 shares of the medical device company’s stock worth $19,307,000 after purchasing an additional 39,300 shares during the last quarter. Finally, Allstate Corp acquired a new position in DexCom during the first quarter worth approximately $247,000. 96.13% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Patrick Michael Murphy sold 400 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $127.03, for a total value of $50,812.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Steven Robert Pacelli sold 3,597 shares of the company’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $116.71, for a total transaction of $419,805.87. Following the completion of the transaction, the executive vice president now owns 72,570 shares of the company’s stock, valued at $8,469,644.70. The disclosure for this sale can be found here. Insiders sold 55,665 shares of company stock valued at $7,344,275 over the last 90 days. Insiders own 0.88% of the company’s stock.

Shares of DXCM stock traded up $2.38 on Wednesday, hitting $154.31. The stock had a trading volume of 180,602 shares, compared to its average volume of 1,226,774. The stock has a market capitalization of $14.00 billion, a price-to-earnings ratio of 514.35 and a beta of 0.80. The business has a 50 day simple moving average of $150.03. The company has a debt-to-equity ratio of 1.56, a current ratio of 6.05 and a quick ratio of 5.64. DexCom, Inc. has a 52-week low of $105.05 and a 52-week high of $161.30.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.07. The business had revenue of $336.40 million during the quarter, compared to the consensus estimate of $304.40 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business’s quarterly revenue was up 38.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.10) earnings per share. Sell-side analysts expect that DexCom, Inc. will post 0.97 earnings per share for the current year.

Several equities analysts recently commented on the stock. BTIG Research reaffirmed a “hold” rating on shares of DexCom in a research report on Thursday, August 1st. Bank of America increased their price objective on shares of DexCom from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Canaccord Genuity increased their price objective on shares of DexCom from $160.00 to $185.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Oppenheimer increased their price objective on shares of DexCom from $167.00 to $180.00 in a research report on Thursday, August 1st. Finally, Robert W. Baird increased their price objective on shares of DexCom from $180.00 to $186.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Six research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $166.75.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: What are benefits of a growth and income fund?

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply